Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
7,519.12
(
0.61%
)
US TECH 100
29,378.83
(
0.57%
)
Dow Jones
50,461.68
(
-0.23%
)
Brent Oil
94.25
(
-2.83%
)
Bitcoin
75,703.54
(
-0.19%
)
News Focus
News Focus
Post# of 257644
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 123024
Boards Moderated 9
Alias Born 09/05/2002

DewDiligence

Member Level

Re: DewDiligence post# 151412

Wednesday, 01/30/2013 1:20:23 PM

Wednesday, January 30, 2013 1:20:23 PM

Post# of 257644
4Q12 Dysport sales* were $74M (€54.7M), -1% YoY:

http://finance.yahoo.com/news/ipsen-fourth-quarter-full-2012-060000994.html

By comparison, AGN’s Botox sales in 3Q12 (a seasonally weak quarter) were $432M, almost 6x Dysport. (AGN reports 4Q12 results on Feb 5.)

*Medical + cosmetic, including sales by Ipsen to VRX.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

Unleash the power of Level 2

Spot liquidity moves with access to US order books.

Sign Up